About SCYNEXIS Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.scynexis.com/
Frequently Asked Questions
What is the 52-week range for SCYX?
The 52-week high is $9.12 and the 52-week low is $3.53.
What is the P/E ratio for SCYX?
The P/E ratio data is currently unavailable.
What is the dividend yield for SCYX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -21.10%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 57.58%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.54.
Analyst Recommendation Trends
Wall Street analyst consensus for SCYX over the last few months:
Latest SCYX News
On Tuesday, there are stocks with unusual volume. Let's take a look.
The trading volume of these stocks is deviating from the norm in today's session.
Scynexis stock surges on $214M BARDA contract for SCY-247
Investing.com -- Scynexis Inc (NASDAQ:SCYX) shares jumped 10% in premarket trading Monday after the company announced it secured a contract from the Biomedical Advanced Research and Development Authority worth up to $214 million.
Scynexis Shares Rise 13.9% After BARDA Awards SCY-247 Development Contract
Scynexis (NASDAQ:SCYX) shares rose 13. 9% in pre-market trading after the company announced a contract with the U.
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health needNon-dilutive funding for SCY-247 enables advancement of a Phase-2 ready program, strengthening the pipeline, enhancing portfolio optionality, and bolstering the Company’s long-term value propositionThe Company does not anticipate any changes to its previously communicated guidance regarding development mileston
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
New director brings nephrology development expertise and over 30 years of experience in the biopharmaceutical industryJERSEY CITY, N.J., Sept. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Steven K. Burke, M.D., to its Board of Directors, effective September 18, 2026. Dr. Burke brings more than 30 years of indu
SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development
Experienced biopharmaceutical and nephrology leader joins SCYNEXIS to advance its rare disease development programsJERSEY CITY, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Todd Minga, M.D. as Senior Vice President, Research & Development, effective September 14, 2026. Dr. Minga brings more than two de
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companiesJERSEY CITY, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (the Company or SCYNEXIS), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appointment of Sanjay Subramanian, MBA, as Chief Financial Officer, effective September 9
SCYNEXIS Appoints Sanjay Subramanian As CFO, Effective September 9
Mr. Subramanian brings more than 20 years of finance, capital markets, business development and operational leadership experience across the biotechnology, pharmaceutical and healthcare sectors. Most recently, he served
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-18 | Burke Steven Keith | +5,750 | - | - |
| 2026-09-18 | Burke Steven Keith | +5,750 | - | - |
| 2026-09-09 | Subramanian Sanjay | +100,000 | - | - |
| 2026-04-01 | Angulo Gonzalez David | +108,695 | - | - |
| 2026-04-01 | Angulo Gonzalez David | +108,695 | - | - |
| 2026-01-29 | Sukenick Scott | +129,833 | - | - |
| 2026-01-29 | Macleod ivor | +129,833 | - | - |
| 2026-01-29 | Angulo Gonzalez David | +391,333 | - | - |
| 2025-10-17 | Angulo Gonzalez David | +32,500 | $0.76 | $24,700 |